Archives des Traitement par agonistes opioïdes

The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial

McAnulty C, Bastien G, Abboud A, Bahremand A, Ledjiar O, Socias ME, Le Foll B, Juteau LC, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. J Subst Use Addict Treat. 2025 Sep;176:209743. doi: 10.1016/j.josat.2025.209743. Epub 2025 Jun 24. PMID: 40571059. CONSULTER

The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial Lire la suite »

Traitement par agonistes opioïdes

Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case-control study

Indigenous peoples and medications for opioid use disorders: A scoping review

The Effect of Opioid Agonist Treatment on Injection-Related Sequelae: A Population-Based Observational Study

The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study

MENU

CONTACT

Centre de Recherche du CHUM

Téléphone

Courriel